Pharmacology & Therapeutics

Article	Citations
Characteristics of anticancer activity of CBP/p300 inhibitors – Features of their classes, intracellular targets and future perspectives of their application in cancer treatment	1109
Editorial Board	371
Unfolded protein responses: Dynamic machinery in wound healing	367
From barbiturates to ganaxolone: The importance of chirality in drug development and in understanding the actions of old and new antiseizure medications	267
Insights into the results of Resmetirom trials: Can a thyroid hormone receptor agonist be the holy grail of MASH therapy?	249
Neurobiological mechanisms of botulinum neurotoxin-induced analgesia for neuropathic pain	226
Treatment of chronic cough: P2X3 receptor antagonists and beyond	197
TAS-102: A resurrected novel Fluoropyrimidine with expanding role in the treatment of gastrointestinal malignancies	191
Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues	175
Immune-related adverse events of cancer immunotherapies targeting kinases	169
Neurosteroids (allopregnanolone) and alcohol use disorder: From mechanisms to potential pharmacotherapy	159
Measuring brain docosahexaenoic acid turnover as a marker of metabolic consumption	159
Pharmaceutical treatment of bone loss: From animal models and drug development to future treatment strategies	147
Targeting adipokines in polycystic ovary syndrome and related metabolic disorders: from experimental insights to clinical studies	139
Inter and intra-tumoral heterogeneity as a platform for personalized therapies in medulloblastoma	136
Pharmacological interventions for intraplaque neovascularization in atherosclerosis	117
Opportunities and challenges in the therapeutic exploitation of histamine and histamine receptor pharmacology in inflammation-driven disorders	114
Organ-on-a-chip platforms as novel advancements for studying heterogeneity, metastasis, and drug efficacy in breast cancer	113
Novel strategies exploiting interleukin-12 in cancer immunotherapy	110
Glucuronidation of orally administered drugs and the value of nanocarriers in strategies for its overcome	109
Biased agonism in drug discovery: Is there a future for biased 5-HT1A receptor agonists in the treatment of neuropsychiatric diseases?	109
Signaling pathways driving ocular malignancies and their targeting by bioactive phytochemicals	108
Targeting the dysfunction of glutamate receptors for the development of novel antidepressants	107
Editorial Board	107
Exploiting the obesity-associated immune microenvironment for cancer therapeutics	103

The role of the STAT3 signaling transduction pathways in radioresistance	100
Current and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy	98
The complex molecular pharmacology of the dopamine D2 receptor: Implications for pramipexole, ropinirole, and rotigotine	97
The unique function of p130Cas in regulating the bone metabolism	96
Multi-omics approaches for biomarker discovery in predicting the response of esophageal cancer to neoadjuvant therapy: A multidimensional perspective	96
Disease progression modeling with temporal realignment: An emerging approach to deepen knowledge on chronic diseases	94
Editorial Board	91
Editorial Board	83
Behavioral characterization, potential clinical relevance and mechanisms of latent pain sensitization	82
Editorial Board	82
Editorial Board	82
Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis	81
Naturally occurring mutations in G protein-coupled receptors associated with obesity and type 2 diabetes mellitus	80
Novel treatments for autism spectrum disorder based on genomics and systems biology	80
Mechanisms and functions of calcium microdomains produced by ORAI channels, d-myo-inositol 1,4,5-trisphosphate receptors, or ryanodine receptors	80
Non-canonical G protein signaling	79
Editorial Board	78
HIV-associated neurotoxicity and cognitive decline: Therapeutic implications	77
The role of lidocaine in cancer progression and patient survival	76
Bioactive lipid regulation of platelet function, hemostasis, and thrombosis	75
Tyrosine kinase and immune checkpoints inhibitors in favorable risk metastatic renal cell carcinoma: Trick or treat?	75
The multifaceted functions of RNA helicases in the adaptive cellular response to hypoxia: From mechanisms to therapeutics	73
Exploring the landscape of post-translational modification in drug discovery	73
Current investigations on clinical pharmacology and therapeutics of Glucose-6-phosphate dehydrogenase deficiency	73
Indirect mediators of systemic health outcomes following nanoparticle inhalation exposure	71
Impact of drug treatment and drug interactions in post-stroke epilepsy	71
Targeting ligand-dependent wnt pathway dysregulation in gastrointestinal cancers through porcupine inhibition	70
Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3	68
Interplay between fat cells and immune cells in bone: Impact on malignant progression and therapeutic response	67
RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives	66
The mystery of the human proton-organic cation antiporter: One transport protein or many?	66
Adenosine receptor signalling as a driver of pulmonary fibrosis	64
Emerging roles of lysophosphatidic acid receptor subtype 5 (LPAR5) in inflammatory diseases and cancer	64
Immunotherapy in melanoma: Can we predict response to treatment with circulating biomarkers?	63
Epigenetic determinants and non-myocardial signaling pathways contributing to heart growth and regeneration	62
Organic cation transporters in psychiatric and substance use disorders	62
Matrikines in the skin: Origin, effects, and therapeutic potential	60
Mechanisms of skeletal muscle-tendon development and regeneration/healing as potential therapeutic targets	60
Chemical inhibitors targeting histone methylation readers	59
Heterogeneity of cGMP signalling in tumour cells and the tumour microenvironment: Challenges and chances for cancer pharmacology and therapeutics	59
Crosstalk between adenosine receptors and CYP450-derived oxylipins in the modulation of cardiovascular, including coronary reactive hyperemic response	59
Inflammation, lipids, and pain in vulvar disease	59
Collateral lethality: A unique type of synthetic lethality in cancers	59
Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination	59
Novel pharmacological strategies to treat cognitive dysfunction in chronic obstructive pulmonary disease	57
Repurposing of pexidartinib for microglia depletion and renewal	57
Medulloblastoma targeted therapy: From signaling pathways heterogeneity and current treatment dilemma to the recent advances in development of therapeutic strategies	57
Unraveling diverse roles of noncoding RNAs in various human papillomavirus negative cancers	57
WITHDRAWN: 17th International conference on bioactive lipids in cancer, inflammation and related diseases virtual special issue	56
The pharmacodynamic and pharmacological mechanisms underlying nanovesicles of natural products: Developments and challenges	56

Editorial Board	56
Potential neonatal toxicity of new psychoactive substances	56
The potential therapeutic strategy in combating neurodegenerative diseases: Focusing on natural products	56
The next frontier in ADME science: Predicting transporter-based drug disposition, tissue concentrations and drug-drug interactions in humans	52
The intricate interactions between inflammasomes and bacterial pathogens: Roles, mechanisms, and therapeutic potentials	52
The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): A lesson from ripretinib	51
The tissue-specific transcriptional landscape underlines the involvement of endothelial cells in health and disease	51
Transcription factors in epithelial ovarian cancer: histotype-specific drivers and novel therapeutic targets	51
Endothelial dysfunction as a complication of anti-cancer therapy	50
Resolving inflammation by TAM receptor activation	50
Ifosfamide - History, efficacy, toxicity and encephalopathy	49
New therapeutic horizons for plasma phospholipid transfer protein (PLTP): Targeting endotoxemia, infection and sepsis	49
Targeting cancer-associated fibroblasts: Challenges, opportunities and future directions	49
Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid	49
Prognostic and predictive molecular biomarkers in advanced colorectal cancer	48
Functional hydrogels as therapeutic tools for spinal cord injury: New perspectives on immunopharmacological interventions	48
Vasculogenic mimicry, a complex and devious process favoring tumorigenesis – Interest in making it a therapeutic target	48
The role and participation of immune cells in the endometrial tumor microenvironment	47
Review: RNA-based diagnostic markers discovery and therapeutic targets development in cancer	47
CYP2J2-mediated metabolism of arachidonic acid in heart: A review of its kinetics, inhibition and role in heart rhythm control	47
SIRT3: A potential therapeutic target for liver fibrosis	47
Toxicology of flavoring- and cannabis-containing e-liquids used in electronic delivery systems	47
Targeted treatment of alcoholic liver disease based on inflammatory signalling pathways	46
In cancer, all roads lead to NADPH	45
Modulation of hyaluronan signaling as a therapeutic target in human disease	45
Probiotics: Potential novel therapeutics for microbiota-gut-brain axis dysfunction across gender and lifespan	45
Inflammation in kidney repair: Mechanism and therapeutic potential	45
The IL-18/IL-18R1 signalling axis: Diagnostic and therapeutic potential in hypertension and chronic kidney disease	45
Is depression the missing link between inflammatory mediators and cancer?	44
Evidence-based pharmacological treatment options for ADHD in children and adolescents	44
Retracing our steps: A review on autism research in children, its limitation and impending pharmacological interventions	44
The regulation of PKA signaling in obesity and in the maintenance of metabolic health	44
Anticancer drug delivery by focused ultrasound-mediated blood-brain/tumor barrier disruption for glioma therapy: From benchside to bedside	43
Neutrophil extracellular traps: A novel target for the treatment of stroke	43
Role of inflammatory chemokines in hypertension	43
Myeloperoxidase: A versatile mediator of endothelial dysfunction and therapeutic target during cardiovascular disease	43
Berberine prevents NAFLD and HCC by modulating metabolic disorders	43
Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease	43
Molecular mechanisms of ferroptosis and their involvement in brain diseases	42
Cellular senescence and hematological malignancies: From pathogenesis to therapeutics	42
The Triple Crown: NO, CO, and H2S in cancer cell biology	42
Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment	42
Targeting mGlu5 for Methamphetamine Use Disorder	41
Hedgehog pathway and its inhibitors in chronic obstructive pulmonary disease (COPD)	41
Overview of the role of purinergic signaling and insights into its role in cancer therapy	41
Editorial Board	40
Editorial Board	40
Editorial Board	40
Arsenic resistance protein 2 and microRNA biogenesis: Biological implications in cancer development	40
Editorial Board	40
Complex in vitro 3D models of digestive system tumors to advance precision medicine and drug testing: Progress, challenges, and trends	40
Editorial Board	40
Editorial Board	40
Editorial Board	40
Comparative efficacy of different treatment modalities in the management of pediatric non-alcoholic fatty liver disease: A systematic review and network meta-analysis	39
Editorial Board	39
The role of osteoprotegerin (OPG) in fibrosis: its potential as a biomarker and/or biological target for the treatment of fibrotic diseases	38
Non-canonical signaling initiated by hormone-responsive G protein-coupled receptors from subcellular compartments	38
Experimental considerations for the assessment of in vivo and in vitro opioid pharmacology	38
Biased agonism at free-fatty acid receptor-4 (FFA4/GPR120)	38
Targeting monocytes/macrophages in fibrosis and cancer diseases: Therapeutic approaches	37
Glyoxalase I is a novel target for the prevention of metabolic derangement	37
Contribution of non-selective membrane channels and receptors in epilepsy	37
Sleep apnea and pulmonary hypertension: A riddle waiting to be solved	37
Preparing to strike: Acute events in signaling by the serpentine receptor for thromboxane A2	37
Editorial Board	37
The new fate of internalized membrane receptors: Internalized activation	36
Endothelial progenitor cells in the host defense response	36
Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches	36
Platelet lipid metabolism in vascular thrombo-inflammation	36
Dual inhibition of butyrylcholinesterase and p38α mitogen-activated protein kinase: A new approach for the treatment of Alzheimer's disease	35
Boron in cancer therapeutics: An overview	35
Pharmacological modulation of respiratory control: Ampakines as a therapeutic strategy	35
The phospholipase A2 superfamily as a central hub of bioactive lipids and beyond	35
The voltage sensitivity of G-protein coupled receptors: Unraveling molecular mechanisms and physiological implications	35
Phosphorylation of nuclear receptors: Novelty and therapeutic implications	35
Myeloid cells in the era of cancer immunotherapy: Top 3 unanswered questions	35
Potassium homeostasis – Physiology and pharmacology in a clinical context	34
C-type natriuretic peptide (CNP): The cardiovascular system and beyond	34
Purinergic signaling in nervous system health and disease: Focus on pannexin 1	33

Endothelial function and dysfunction: Impact of sodium-glucose cotransporter 2 inhibitors	33
Nitrite and myocardial ischaemia reperfusion injury. Where are we now?	33
Regulatory lipid vicinal diols counteract the biological activity of epoxy fatty acids and can act as biomarkers and mechanisms for disease progression	33
Development and clinical translation of P2X7 receptor antagonists: A potential therapeutic target in coronary artery disease?	33
Targeting selective autophagy in CNS disorders by small-molecule compounds	33
Is the peroxisome proliferator-activated receptor gamma a putative target for epilepsy treatment? Current evidence and future perspectives	32
Potential targeting of the tumor microenvironment to improve cancer virotherapy	32
Pulmonary vascular fibrosis in pulmonary hypertension – The role of the extracellular matrix as a therapeutic target	32
Prognostic significance and therapeutic implications of Caveolin-1 in gastrointestinal tract malignancies	31
GABAkines – Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors	31
PARkinson's: From cellular mechanisms to potential therapeutics	31
Corrigendum to “Apical sodium-dependent bile acid transporter, drug target for bile acid related diseases and delivery target for prodrugs: Current and future challenges” [Pharmacology & Therapeut	30
Annexin A1 in neurological disorders: Neuroprotection and glial modulation	30
Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance	30
Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases	30
The endocrine FGFs axis: A systemic anti-fibrotic response that could prevent pulmonary fibrogenesis?	30
Pharmacological data science perspective on fatal incidents of morphine treatment	30
Attributes novel drug candidate: Constitutive GPCR signal bias mediated by purinergic receptors	30
Sulfoconjugation of protein peptides and glycoproteins in physiology and diseases	30
Cell-based therapies for vascular regeneration: Past, present and future	29
Cannabinoids and the endocannabinoid system in fibromyalgia: A review of preclinical and clinical research	29
Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential	29
Hypertension & dementia: Pathophysiology & potential utility of antihypertensives in reducing disease burden	29
Cytochrome P450-derived fatty acid epoxides and diols in angiogenesis and stem cell biology	29
Pharmacological targets and emerging treatments for respiratory syncytial virus bronchiolitis	29
Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach	28
Following the design path of isoform-selective Hsp90 inhibitors: Small differences, great opportunities	28
TAAR1 as an emerging target for the treatment of psychiatric disorders	28
Dissecting the relationship between antimicrobial peptides and mesenchymal stem cells	28
Orthotopic and metastatic tumour models in preclinical cancer research	28
Cancer metastasis: Molecular mechanisms and clinical perspectives	28
Targeting the p38α pathway in chronic inflammatory diseases: Could activation, not inhibition, be the appropriate therapeutic strategy?	28
The role of sphingosine 1-phosphate metabolism in brain health and disease	28
Imaging neuroinflammation with TSPO: A new perspective on the cellular sources and subcellular localization	28
The gabapentinoid drugs and their abuse potential	27
Dysregulation of metabolic pathways in pulmonary fibrosis	27
SARS-CoV-2 and other coronaviruses negatively influence mitochondrial quality control: beneficial effects of melatonin	27
Stepping forward in antibody-drug conjugate development	27
Branched and linear fatty acid esters of hydroxy fatty acids (FAHFA) relevant to human health	27
Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics	27
Medicinal chemistry, pharmacology, and therapeutic potential of α-conotoxins antagonizing the α9α10 nicotinic acetylcholine receptor	27
Immunomodulation and targeted drug delivery with high intensity focused ultrasound (HIFU): Principles and mechanisms	27
Recent advances and future perspectives on carbohydrate-based cancer vaccines and therapeutics	27
Targeting post-translational histone modifying enzymes in glioblastoma	27
Aging-related modifications to G protein-coupled receptor signaling diversity	26
Macrophage immunometabolism in inflammatory bowel diseases: From pathogenesis to therapy	26
Kynurenine emerges from the shadows – Current knowledge on its fate and function	26
Understanding the physiological role of NaV1.9: Challenges and opportunities for pain modulation	26
UFMylation: An integral post-translational modification for the regulation of proteostasis and cellular functions	25
Review of the application of Kirchhoff's Laws of series and parallel flows to pharmacology: Defining organ clearance	25
Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety	25
Triggering receptor expressed on myeloid cells-1 (TREM-1) inhibition in atherosclerosis	25
Programming inflammatory cell death for therapy	25
Extracellular vesicles in cancer diagnostics and therapeutics	25
Time is of the essence: Coupling sleep-wake and circadian neurobiology to the antidepressant effects of ketamine	24
Understanding the molecular bridges between the drugs and immune cell	24
Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials	24
Targeting the NLRP3 inflammasome in cardiovascular diseases	24
Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets	24
Bioactive lipids in the skin barrier mediate its functionality in health and disease	24
Advances in anticancer alkaloid-derived metallo-chemotherapeutic agents in the last decade: Mechanism of action and future prospects	24
New advances in pharmacoresistant epilepsy towards precise management-from prognosis to treatments	24
PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets	23
Short-chain fatty acid receptors and gut microbiota as therapeutic targets in metabolic, immune, and neurological diseases	23
Circular RNAs in cardiovascular diseases	23
Use of big data and machine learning algorithms to extract possible treatment targets in neurodevelopmental disorders	22
Pharmacological treatment of cardiogenic shock – A state of the art review	22
Treating exuberant, non-resolving inflammation in the lung; Implications for acute respiratory distress syndrome and COVID-19	22
TLR4 biased small molecule modulators	22
Targeting organ-specific mitochondrial dysfunction to improve biological aging	22
Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives	22
Review: Sex-related differences in the treatment of cardiac arrhythmia	22
Editorial Board	22
Stem cell therapy in liver regeneration: Focus on mesenchymal stem cells and induced pluripotent stem cells	22
Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors	22
Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases	22
Why medicines work	22
Editorial Board	22
Bispecific antibodies for the treatment of neuroblastoma	22
The central role of IL-33/IL-1RL1 pathway in asthma: From pathogenesis to intervention	22
Intercellular pathways of cancer treatment-related cardiotoxicity and their therapeutic implications: the paradigm of radiotherapy	22
Editorial Board	21
Corrigendum to “Functional and Biochemical Consequences of Disease Variants in Neurotransmitter Transporters: A Special Emphasis on Folding and Trafficking Deficits” [Pharmacology & Therapeutics 2	21
Clinical implications of tristetraprolin (TTP) modulation in the treatment of inflammatory diseases	21
Editorial Board	21
Editorial Board	21
Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder	21
Cholesterol crystals and atherosclerotic plaque instability: Therapeutic potential of Eicosapentaenoic acid	21
Editorial Board	21
Immune cells and their derived microRNA-enriched extracellular vesicles in nonalcoholic fatty liver diseases: Novel therapeutic targets	21
Non-cytochrome P450 enzymes involved in the oxidative metabolism of xenobiotics: Focus on the regulation of gene expression and enzyme activity	21
Essential role of sulfide oxidation in brain health and neurological disorders	20
The role of FOXP3 in non-small cell lung cancer and its therapeutic potentials	20
Natural products that alleviate depression: The putative role of autophagy	20
RGS proteins, GRKs, and beta-arrestins modulate G protein-mediated signaling pathways in asthma	20